Resources


PUBLISHED: 2018 CATEGORY: Adults, Seniors, New Canadians, Travellers, Health care providers TYPE: PDFAdult immunization: What vaccines do you need?

Adult immunization: What vaccines do you need?

Corporate Authors: Immunize Canada
Publisher: Immunize Canada


PUBLISHED: 2018 CATEGORY: Health care providers TYPE: External Link Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials

Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials

An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged >50 and >70 years (ZOE-50 and ZOE-70, respectively). Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against
mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases.

Authors: Kovac M et al.
Journal Issue: 12
Journal Title: Vaccine
Journal Volume: 36
Publisher: Elsevier

PUBLISHED: 2018 CATEGORY: Health care providers TYPE: External Link Intranasal influenza vaccine: Why does Canada have different recommendations from the USA on its use?

Intranasal influenza vaccine: Why does Canada have different recommendations from the USA on its use?

Canada and the USA differ in their recommendations for the use of live attenuated influenza vaccine (LAIV). The Canadian National Advisory Committee on Immunization (NACI) continues to recommend LAIV as one of the influenza vaccines available for use in children 2 to 17 years of age. The US Advisory Committee on Immunization Practices made an interim recommendation against the use of LAIV for the 2016-2017 influenza season in response to low LAIV effectiveness observed in the USA during the 2013-2014 to 2015-2016 seasons. The recommendation has been continued for the 2017-2018 season. In response, NACI undertook a review of available LAIV effectiveness data in children and adolescents from Canada, the USA and a number of European countries. This commentary by Canada’s Chief Public Health Officer summarizes the findings of that review and provides the rationale for Canada’s current continued recommendation for LAIV use.

Authors: Tam TWS
Journal Issue: 1
Journal Title: Paediatrics & Child Health
Journal Volume: 23
Publisher: Oxford Academic

PUBLISHED: 2018 CATEGORY: Health care providers TYPE: External Link Is varicella vaccination associated with pediatric arterial ischemic stroke? A population-based cohort study

Is varicella vaccination associated with pediatric arterial ischemic stroke? A population-based cohort study

No increased risk of arterial ischemic stroke was found after varicella (chickenpox) vaccination. Parents and clinicians should be reassured about the safety of the varicella vaccine.

Authors: MacDonald SE et al.
Journal Issue: 11 April 2018
Journal Title: Vaccine
Publisher: Elsevier

PUBLISHED: 2018 CATEGORY: Les fournisseurs de soins TYPE: External Link La « littératie vaccinale » : les stratégies et connaissances pour promouvoir la vaccination

La « littératie vaccinale » : les stratégies et connaissances pour promouvoir la vaccination

La littératie en santé influence la capacité des gens à s’engager dans des activités de prévention. Parmi les trois déterminants de l’hésitation vaccinale – la confiance, la complaisance et la commodité – le dernier est concerné lorsque, entre autres facteurs, la capacité à comprendre (savoir le langage) peut avoir un impact sur la décision de se faire vacciner.

Authors: Bucci LM
Corporate Authors: Immunisation Canada

PUBLISHED: 2018 CATEGORY: Les fournisseurs de soins TYPE: External Link Les recommandations relatives aux vaccins antigrippaux administrés aux enfants et aux adolescents pour la saison 2017-2018

Les recommandations relatives aux vaccins antigrippaux administrés aux enfants et aux adolescents pour la saison 2017-2018

La Société canadienne de pédiatrie continue d’encourager la vaccination antigrippale annuelle de TOUS les enfants et les adolescents, dès l’âge de six mois. Les recommandations du Comité consultatif national de l’immunisation (CCNI) pour la saison 2017-2018 n’ont pas subi de changements importants par rapport à la saison précédente. Le CCNI a analysé toutes les données sur l’efficacité du vaccin vivant atténué contre l’influenza (VVAI) sur le marché et conclut qu’elles en appuient l’utilisation au Canada, même si les États-Unis ne le recommandent pas en raison de doutes quant à son efficacité.

Authors: Moore DL
Journal Issue: 1
Journal Title: Paediatrics & Child Health
Journal Volume: 23
Publisher: Oxford Academic



PUBLISHED: 2018 CATEGORY: Les fournisseurs de soins TYPE: External Link Mise à jour sur la vaccination contre la méningococcie invasive chez les enfants et les adolescents canadiens

Mise à jour sur la vaccination contre la méningococcie invasive chez les enfants et les adolescents canadiens

Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least 2 months of age.

Authors: Robinson JL
Journal Issue: 1
Journal Title: Paediatrics & Child Health
Journal Volume: 23
Publisher: Oxford Academic